TNF and COVID-19: Thus, systemic glucocorticoid pretreatment was reported to represent a risk factor for severe COVID-19 (OR, 6.9; 95% CI, 2.3–20.5) in patients with inflammatory bowel disease, while anti-TNFα treatment presents no association (Brenner et al., 2020).